Inhibitex, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 65

Inhibitex, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Inhibitex, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Inhibitex, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Inhibitex, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Inhibitex, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Inhibitex, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Inhibitex, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Inhibitex, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Inhibitex, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Inhibitex, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Inhibitex, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Inhibitex, Inc. Snapshot
Inhibitex, Inc. Overview
Key Information
Key Facts
Inhibitex, Inc. – Research and Development Overview
Key Therapeutic Areas
Inhibitex, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Inhibitex, Inc. – Pipeline Products Glance
Inhibitex, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Inhibitex, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Inhibitex, Inc. – Drug Profiles
Aurexis
Product Description
Mechanism of Action
R&D Progress
FV-100
Product Description
Mechanism of Action
R&D Progress
INX-189
Product Description
Mechanism of Action
R&D Progress
INH-001
Product Description
Mechanism of Action
R&D Progress
Inhibitex, Inc. – Pipeline Analysis
Inhibitex, Inc. – Pipeline Products by Therapeutic Class
Inhibitex, Inc. Pipeline Products By Target
Inhibitex, Inc. – Pipeline Products by Route of Administration
Inhibitex, Inc. – Pipeline Products by Molecule Type
Inhibitex, Inc. – Recent Pipeline Updates
Inhibitex, Inc. – Company Statement
Inhibitex, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 02, 2010: Inhibitex Announces Data Presentations On INX-189 At Annual Meeting Of American Association For Study Of Liver Diseases
Nov 01, 2010: Inhibitex Initiates Phase Ib Multiple Ascending Dose Trial Of INX-189 In Patients With Chronic Hepatitis C
Oct 15, 2010: Inhibitex Completes Enrollment In Phase II Clinical Trial Of FV-100 In Shingles Patients
Sep 01, 2010: Inhibitex Successfully Completes Phase Ia Trial Of INX-189 For HCV Infections
Jul 22, 2010: Inhibitex Reports Independent Data Safety Monitoring Board Recommends Continuation Of Phase II Clinical Trial Of FV-100
Apr 12, 2010: Inhibitex Reports Results Of Interim Analysis Of Phase II Clinical Trial Of FV-100
Apr 12, 2010: Inhibitex Reports Results Of Interim Analysis Of Phase II Clinical Trial Of FV-100
May 08, 2009: Phase II Clinical Trial Initiation Of FV-100 For The Treatment Of Shingles
May 01, 2008: Phase I Initiation Of FV 100 For The Treatment Of Shingles
Dec 14, 2007: Inhibitex Phase I clinical trial Results Of FV-100 For The Treatment Of Shingles
Financial Deals Landscape
Inhibitex, Inc., Deals Volume Summary, 2004 to YTD 2010
Inhibitex, Inc., Deals Summary By Region, 2004 to YTD 2010
Inhibitex, Inc., Deals Summary, 2004 to YTD 2010
Inhibitex, Inc. Detailed Deal Summary
Acquisition
Inhibitex Acquires Fermavir Pharmaceuticals
Venture Financing
Inhibitex Raises $20 Million In Financing Round
Inhibitex Secures $45 Million In Series D Financing
Equity Offering
Inhibitex Completes Private Placement Of $23 Million
Inhibitex Completes Private Placement Of $0.14 Million
Inhibitex Completes Private Placement Of $0.12 Million
Inhibitex Completes Private Placement Of $0.53 Million
Inhibitex Completes Private Placement Of $41 Million
Inhibitex Completes Private Placement Of $2 Million
Inhibitex Completes Private Placement Of $50 Million
Inhibitex Completes Initial Public Offering Of $39 Million
Debt Offering
Inhibitex Completes Private Placement Of $0.075 Million
Inhibitex Enters Into Agreement With Dyax
Licensing Agreements
Inhibitex Enters Into Licensing Agreement With Cardiff University And Katholieke Universiteit
Inhibitex Enters Into Licensing Agreement With The University Of Georgia
Inhibitex Enters Into Licensing Agreement With 3M
Inhibitex Enters Into Licensing Agreement With Xenotope Diagnostics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Defense Robotics - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Private Tutoring - Global Strategic Business Report